|
"yen c j"的相關文件
顯示項目 381-390 / 471 (共48頁)
<< < 34 35 36 37 38 39 40 41 42 43 > >>
每頁顯示[10|25|50]項目
| 臺大學術典藏 |
2018-09-10T08:06:10Z |
Metabolic risks, white matter hyperintensities, and arterial stiffness in high-functioning healthy adults
|
Hwang, JJ;Lin, LY;Hwang, Juey-Jen;Lin, Lian-Yu;Yu, YH;Yu, Yau-Hua;Chang, CC;Chang, Chien-Cheng;Chang, KJ;HON-MAN LIU;Chang, King-Jen;Yen, CJ;Yen, Chung-Jen;LIAN-YU LIN;Liu, HM;CHUNG-JEN YEN;CY;Liu, Hon-Man;Chen, Ching-Yu;JUEY-JEN HWANG;Chen;Kuo, Hsu-Ko;Kuo, HK;CHING-YU CHEN;Hwang, J.-J.;Lin, L.-Y.;Yu, Y.-H.;Chang, C.-C.;Chang, K.-J.;Yen, C.-J.;Liu, H.-M.;Chen, C.-Y.;Kuo, H.-K.; Kuo, H.-K.; Chen, C.-Y.; Liu, H.-M.; Yen, C.-J.; Chang, K.-J.; Chang, C.-C.; Yu, Y.-H.; Lin, L.-Y.; Hwang, J.-J.; CHING-YU CHEN; Kuo, HK; Kuo, Hsu-Ko; Chen; JUEY-JEN HWANG; Chen, Ching-Yu; Liu, Hon-Man; CY; CHUNG-JEN YEN; Liu, HM; LIAN-YU LIN; Yen, Chung-Jen; Yen, CJ; Chang, King-Jen; HON-MAN LIU; Chang, KJ; Chang, Chien-Cheng; Chang, CC; Yu, Yau-Hua; Yu, YH; Lin, Lian-Yu; Hwang, Juey-Jen; Lin, LY; Hwang, JJ |
| 臺大學術典藏 |
2018-09-10T05:49:27Z |
Effects of intraperitoneal antibiotics on human peritoneal mesothelial cell growth
|
Yen, C.-J.;Tsai, T.-J.;Chen, H.-S.;Fang, C.-C.;Yang, C.-C.;Lee, P.-H.;Lin, R.-H.;Tasi, K.-S.;Hung, K.-Y.;Yen, T.-S.; CHENG-CHUNG FANG |
| 臺大學術典藏 |
2018-09-10T05:44:56Z |
Diltiazem suppresses collagen synthesis and IL-1β-induced TGF-β1 production on human peritoneal mesothelial cells
|
Fang, C.-C.;Yen, C.-J.;Chen, Y.-M.;Chu, T.-S.;Lin, M.-T.;Yang, J.-Y.;Tsai, T.-J.; CHENG-CHUNG FANG; TZONG-SHINN CHU; MING-TSAN LIN; CHUNG-JEN YEN; TUN-JUN TSAI; YUNG-MING CHEN |
| 臺大學術典藏 |
2018-09-10T05:18:15Z |
Interaction of the G182C polymorphism in the APOA5 gene and fasting plasma glucose on plasma triglycerides in Type 2 diabetic subjects
|
Jiang, Y.-D. and Yen, C.-J. and Chou, W.-L. and Kuo, S.-S. and Lee, K.-C. and Chiu, K.C. and Chuang, L.-M.; 莊立民; Jiang, Y.-D.; Yen, C.-J.; Chou, W.-L.; Kuo, S.-S.; Lee, K.-C.; Chiu, K. C.; Chuang, L.-M.; YI-DER JIANG; CHUNG-JEN YEN; Jiang, Y.-D.; Yen, C.-J.; LEE-MING CHUANG; Chou, W.-L.; Kuo, S.-S.; Lee, K.-C.; Chiu, K. C.; Chuang, L.-M. |
| 臺大學術典藏 |
2018 |
Diabetes mellitus, superoxide dismutase and peroxisome proliferator activated receptor gamma polymorphisms modify the outcome of end-stage renal disease patients of Han Chinese origin
|
Chao C.-T.;Jenq-Wen Huang;Chiang C.-K.;Chen Y.-C.;Fang C.-C.;Hu F.-C.;Chang C.-C.;Yen C.-J.; Chao C.-T.; JENQ-WEN HUANG; Chiang C.-K.; Chen Y.-C.; Fang C.-C.; Hu F.-C.; Chang C.-C.; Yen C.-J. |
| 國立成功大學 |
2018 |
The interplay between oral microbiome, lifestyle factors and genetic polymorphisms in the risk of oral squamous cell carcinoma
|
Hsiao, J.-R.;Chang, Chang C.-C.;Lee, W.-T.;Huang, C.-C.;Ou, C.-Y.;Tsai, S.-T.;Chen, K.-C.;Huang, J.-S.;Wong, T.-Y.;Lai, Y.-H.;Wu, Y.-H.;Hsueh, W.-T.;Wu, S.-Y.;Yen, C.-J.;Chang, J.-Y.;Lin, C.-L.;Weng, Y.-L.;Yang, H.-C.;Chen, Y.-S.;Chang, J.S. |
| 國立成功大學 |
2018 |
Hepatitis B virus surface gene pre-S2 mutant as a high-risk serum marker for hepatoma recurrence after curative hepatic resection
|
Yen, C.-J.;Ai, Y.-L.;Tsai, H.-W.;Chan, S.-H.;Yen, C.-S.;Cheng, K.-H.;Lee, Y.-P.;Kao, C.-W.;Wang, Y.-C.;Chen, Y.-L.;Lin, C.-H.;Liu, T.;Tsai, H.-P.;Wang, J.-R.;Su, I.-J.;Huang, W. |
| 國立成功大學 |
2018 |
Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma
|
Abou-Alfa, G.K.;Qin, S.;Ryoo, B.-Y.;Lu, S.-N.;Yen, C.-J.;Feng, Y.-H.;Lim, H.Y.;Izzo, F.;Colombo, M.;Sarker, D.;Bolondi, L.;Vaccaro, G.;Harris, W.P.;Chen, Z.;Hubner, R.A.;Meyer, T.;Sun, W.;Harding, J.J.;Hollywood, E.M.;Ma, J.;Wan, P.J.;Ly, M.;Bomalaski, J.;Johnston, A.;Lin, C.-C.;Chao, Y.;Chen, L.-T. |
| 國立成功大學 |
2018 |
Ramucirumab safety in East Asian patients: A meta-analysis of six global, randomized, double-blind, placebo-controlled, phase III clinical trials
|
Yen, C.-J.;Muro, K.;Kim, T.-W.;Kudo, M.;Shih, J.-Y.;Lee, K.-W.;Chao, Y.;Kim, S.-W.;Yamazaki, K.;Sohn, J.;Cheng, R.;Zhang, Y.;Binder, P.;Mi, G.;Orlando, M.;Chung, H.C. |
| 國立成功大學 |
2018 |
Phase II studies with refametinib or refametinib plus sorafenib in patients with RAS-mutated hepatocellular Carcinoma
|
Lim, H.Y.;Merle, P.;Weiss, K.H.;Yau, T.;Ross, P.;Mazzaferro, V.;Blanc, J.-F.;Ma, Y.T.;Yen, C.J.;Kocsis, J.;Choo, S.P.;Sukeepaisarnjaroen, W.;Gerolami, R.;Dufour, J.-F.;Gane, E.J.;Ryoo, B.-Y.;Peck-Radosavljevic, M.;Dao, T.;Yeo, W.;Lamlertthon, W.;Thongsawat, S.;Teufel, M.;Roth, K.;Reis, D.;Childs, B.H.;Krissel, H.;Llovet, J.M. |
顯示項目 381-390 / 471 (共48頁)
<< < 34 35 36 37 38 39 40 41 42 43 > >>
每頁顯示[10|25|50]項目
|
